Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Butowski

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
Neuro-Oncology|October 10, 2015
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II studyNicholas Butowski, Howard Colman, John F De Groot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcomaMichael D Prados, Susan M Chang, Nicholas Butowski, et al.
Neuro-Oncology|January 14, 2023
Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trialJohn H Sampson, Achal Singh Achrol, Manish K Aghi, et al.
Neuro-Oncology|October 28, 2017
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastomaHui K Gan, David A Reardon, Andrew B Lassman, et al.
Neuro-Oncology|January 17, 2019
Advances in multidisciplinary therapy for meningiomasPriscilla K Brastianos, Evanthia Galanis, Nicholas Butowski, et al.
Scientific Reports|August 28, 2024
Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade gliomaAubrey Ledford, Analiz Rodriguez, Lindsay Lipinski, et al.
Neuro-Oncology Advances|December 23, 2020
Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsJessica D Schulte, Robin A Buerki, Sarah Lapointe, et al.
Neuro-Oncology|April 6, 2021
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomasYao Yu, Javier Villanueva-Meyer, Matthew R Grimmer, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Neuro-Oncology|October 10, 2015
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II studyNicholas Butowski, Howard Colman, John F De Groot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcomaMichael D Prados, Susan M Chang, Nicholas Butowski, et al.
Neuro-Oncology|January 14, 2023
Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trialJohn H Sampson, Achal Singh Achrol, Manish K Aghi, et al.
Neuro-Oncology|October 28, 2017
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastomaHui K Gan, David A Reardon, Andrew B Lassman, et al.
Neuro-Oncology|January 17, 2019
Advances in multidisciplinary therapy for meningiomasPriscilla K Brastianos, Evanthia Galanis, Nicholas Butowski, et al.
Scientific Reports|August 28, 2024
Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade gliomaAubrey Ledford, Analiz Rodriguez, Lindsay Lipinski, et al.
Neuro-Oncology Advances|December 23, 2020
Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsJessica D Schulte, Robin A Buerki, Sarah Lapointe, et al.
Neuro-Oncology|April 6, 2021
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomasYao Yu, Javier Villanueva-Meyer, Matthew R Grimmer, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
Pageof 10